MARKSANS vs VENUSREM: Stock Comparison
MARKSANS PHARMA is the larger company by market capitalisation. MARKSANS PHARMA shows a higher ROCE and a higher net margin, while VENUSREM shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
MARKSANS leads 5; VENUSREM leads 8 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | MARKSANS | VENUSREM |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | MARKSANS | VENUSREM |
|---|---|---|
| Live Price | ₹326.75 | ₹1,797.5 |
| Day Change | -1.64% | 4.8% |
| Volume | 16.54 L | 2.46 L |
| 52-Week High | ₹345.5 | ₹1,800.8 |
| 52-Week Low | ₹155 | ₹424 |
| Distance from 52W High | -5.43% | -0.18% |
Valuation
| Metric | MARKSANS | VENUSREM |
|---|---|---|
| Market Cap | ₹14,877 Cr | ₹2,279 Cr |
| P/E Ratio | 29.56x | 18.81x |
| P/B Ratio | 5.05x | 3.29x |
| EPS | ₹3.47 | ₹19.1 |
| Book Value | ₹67.36 | ₹496.56 |
| Dividend Yield | 0.28% | 0.6% |
Growth
| Metric | MARKSANS | VENUSREM |
|---|---|---|
| Revenue Growth (TTM YoY) | 20.8% | 33% |
| EPS Growth (TTM YoY) | 63.5% | 126.4% |
| Qtr Sales Growth | 161.78% | -0.03% |
| Qtr Profit Growth | 130.9% | 11.14% |
Profitability & Leverage
| Metric | MARKSANS | VENUSREM |
|---|---|---|
| ROE | 13.76% | 15.48% |
| ROCE | 17.9% | 16.1% |
| Net Margin | 14.16% | 13.35% |
| Operating Margin | 19.81% | 17.44% |
| Debt to Equity | 0.01x | 0x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | MARKSANS | VENUSREM |
|---|---|---|
| Promoter Holding | 43.87% | 41.76% |
| FII Holding | 17.47%▲ 0.71 pp | 2.92%▲ 0.12 pp |
| DII Holding | 6.19%▼ 0.38 pp | 0.89%▼ 0.31 pp |
| Public Holding | 32.47%▼ 0.32 pp | 54.43%▲ 0.19 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: MARKSANS PHARMA and VENUSREM.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.